A Study of NDI 1150-101 in Patients With Solid Tumors

Key Inclusion Criteria: * Life expectancy of ≥ 12 weeks * Measurable or non-measurable disease for Dose Escalation; measurable disease using RECIST v1.1 is required for Dose Expansion * Recovered from prior therapy to Grade ≤ 1 or return to baseline status (except for alopecia) * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Patients with adequate bone marrow, kidney and liver function * Last dose of previous anticancer therapy ≥ 4 weeks prior to first dose of NDI-101150; includes prior anti-PD-1 or anti-PD-L1 therapy, other anticancer therapy, radiotherapy, or surgical intervention * For Dose Escalation Phase Only (Dose Escalation, Monotherapy and Combination Therapy): Histologically or cytologically confirmed advanced or metastatic solid tumors for whom no standard therapies are available or refractory to standard therapy * For Dose Expansion Phase (Dose Expansion, Monotherapy and Combination Therapy): Willing to consent to required tumor biopsy(ies). Histologically or cytologically confirmed advanced or metastatic G/GEJ, NSCLC or RCC for which no standard therapy is available or are refractory to standard therapy Key Exclusion Criteria: * Previous solid organ or hematopoietic cell transplant * Central nervous system (CNS) malignant disease not previously treated, active leptomeningeal disease, uncontrolled symptomatic CNS involvement, or CNS malignant disease requiring steroid or other therapeutic intervention * Prior anticancer therapy within 2-6 w…